 The company was on the brink of collapse brought down by an accounting scandal that earned it the label of "Europe's Enron".During his tenure, Armen became the architect of the company's $1 billion restructuring program by strengthening Élan's finances, refocusing the group on its core clinical development business and returning shareholder value.On the day that Armen assumed chairmanship, the "Wall Street Journal" and BBC discussed the restructuring plan in some detail.